Unlock potential with expert consulting services.
Empowering Research & Educational Growth
Unlock potential with expert consulting services.
About AHAD
Expert Research and Educational Empowerment
American Health and Diagnostics Institute (AHAD) specializes and facilitates creative and innovative research, research training and academic curricular excellence related to biomedicine, disease diagnostics and impactful health programs.
With combined academic and research experience related to biomedicine, therapeutic and biomarker development exceeding 70 years, AHAD’s team of experts has an enviable track record of delivering cutting-edge science, whether in the lab, classroom and professional program development, with our activities focusing on two much-in-demand domains:
Development and evaluation of diagnostic tests using state-of-the-art technology;
Development and launching of innovative empowering academic programs, particularly those underrepresented in international universities and developing economies.
MISSION
Development and facilitating state-of-the-art academic and research training and degree-granting programs per international standards as an imperative of empowerment and advancement.
Our Capacity
Located in the state-of-the-art Rensselaer Technology Park (of Rensselaer Polytechnic Institute), AHAD houses cutting-edge research facilities for collaborative research in biotechnology and nanotechnology with a focuse of training and innovation in biomedicine, drug development, graduate research, conferences and workshops. Closely affiliated with several patent-holding concerns such as Vascular Vision Pharmaceuticals, Nanopharmaceuticals, LLC, and Virothera Pharmaceuticals, LLC, AHAD collaborates with domestic and international organizations and universities in empowering quality research and academics.
Our Services
We offer a wide range of services to support educational programs and research excellence that is innovative, holistic and empowering.
OUR FOUNDERS
Shaker A. Mousa, PhD, MBA, FACC, FACB, FNAI
Shaker A. Mousa, PhD, MBA, FACC, FACB, FNAI
Shaker A. Mousa, PhD, MBA, FACC, FACB, FNAI
Dr. Mousa, professor of Pharmacology, president and Board Chairman of Virothera Pharmaceuticals LLC and founders of several spin-off Pharmaceutical and biotechnology companies focusing on the treatment of various blood, vascular disorders, hematological and Oncological diseases. He held a senior scientist and a research fellow at DuPont Pharmaceuticals and DuPont Merck for two decades. He is Visiting Scholar at Various Universities. Awarded the 2017 Kuwait Foundation for Advancement in Sciences (KFAS) Laureate for Applied Sciences in Medicine. Elected and inducted in 2018, a fellow of the National Academy of Inventors (FNAI), and awarded 2020 First Sheikh Zeid award in Integrative and Complementary Medicine.
Dr. Mousa contributes to the success of several regional, national, and international academic, biotechnology and pharmaceutical institutes. Dr. Mousa’s expertise in drug discovery and development during his 17 years at DuPont-Merck Pharmaceuticals helped facilitate the success of several start up regional, national biotechnology and pharmaceutical companies. These include the followings: Emisphere Technologies, AGTT Pharmaceuticals, Delcath Systems Inc., Cytogel, Inc., SelectX Pharmaceuticals, Vascular Vision Pharmaceuticals Co., Othera Pharmaceuticals, PolyMedix, Pharmion Corp, Nova Decision, DuPont, Merck, Sanofi-Aventis,GlaxoSmithKline, Pfizer, AstraZeneca, Leo Pharm, Takeda, Abbott, Hospira, Eisaipharmaceuticals, EndoPharmaceuticals, and several other biotech and pharmaceutical companies.
One of Dr. Mousa's passions is fostering interest in research among students. Additionally, Dr. Mousa established several exchange programs with Universities from the Middle East, Europe, Japan, China, South Korea, and others.
Dr Mousa received a Ph.D. in Pharmacology from Ohio State University in Columbus, Ohio, completed postdoctoral research in Cardiovascular Pharmacology at the University of Kentucky in Lexington, Kentucky, and earned his MBA from Widener University in Chester, Pennsylvania.
Hassan A. N. El-Fawal, PhD
Shaker A. Mousa, PhD, MBA, FACC, FACB, FNAI
Shaker A. Mousa, PhD, MBA, FACC, FACB, FNAI
Dr. El-Fawal earned a BS in Agriculture and Environmental Sciences, majoring in Entomology and Pesticide Chemistry from the University of Alexandria. He spent nearly two years at Cornell University as an Independent Studies student taking courses in Neuroscience, Pharmacology and Toxicology. He worked as a chemical compounder in both generic pharmaceuticals and solvent industries. He went on to earn an MS in Biomedical Sciences (Pharmacology and Toxicology) at the University of Guelph in Ontario Canada and a PhD from Virginia-Maryland College of Veterinary Medicine at Virginia Tech.
After a brief stint at the US Environmental Protection Agency’s Biomarkers Laboratory in Research Triangle Park, El-Fawal joined New York University Medical Center’s Institute of Environmental Medicine. El-Fawal has been in numerous academic leadership roles, including Associate Chair and Chair of the Division of Natural Sciences and Veterinary Technology at Mercy University and Professor of Biomedical and Health Sciences, Founding Dean of the School of Health Sciences at Albany College of Pharmacy and Health Sciences, Dean of Sciences and Engineering at the American University in Cairo. In the latter, he founded and directed the Institute of Global Health and Human Ecology with its MPH and PhD in Global Public Health. He also directed the MS in Sustainable Development for two years. While in Cairo, he also established the Central Neuromics and Sequencing (CNS), Environmental Assessment od Risks and Toxics on Health (EARTH) and the Center of Applied Research on the Environment and Sustainability (CARES) research facilities.
In an academic career that has spanned 35 years, he has developed and launched numerous programs in health sciences and professions and overseen their accreditation.
He is a researcher in the areas of environmental health, biomarkers and neurodegeneration.
OUR TRACK RECORD
ACADEMICS
INNOVATION, QUALITY, SYNERGY
INNOVATION, QUALITY, SYNERGY
Academics [NYU Medical Center; Mercy University, State University of New York (SUNY), Albany College of Pharmacy, American University in Cairo, Johns Hopkins University, Temple University, RPI, Albany Medical Center, King Saud University, King Abdulaziz University]
•Unique curricular development in support of health professions, including medicine, pharmacy, rehabilitation professions, and environmental health; •Introduction and launching of sustainable development infrastructure and programs; •Founding of global public health, human ecology institutions and programs; •Founding of accredited and accreditation-eligible programs in clinical laboratory sciences, molecular cytology, global health, nanomedicine, sustainable development, environmental safety, physical and occupational therapy, speech pathology, physician assistant studies and health entrepreneurship. •Exchange programs with Universities from the Middle East, Europe, Japan, China, South Korea, and others.
INNOVATION, QUALITY, SYNERGY
INNOVATION, QUALITY, SYNERGY
INNOVATION, QUALITY, SYNERGY
Academic Biomedical and Health Curriculum Development in Health Professions and Accreditation
•MSc and DPT Physical Therapy •MSc Occupational Therapy •MPS Physician Assistant Studies •MSc Speech Pathology •MSc Advanced Nurse Practitioner •BSc Environmental Health and Safety •MSc Biotechnology •BSc and MS Clinical Laboratory Science •BS and MS Molecular Cytology and Cytotechnology •Certificate in NanoMedicine •Global Health and Human Ecology •MPH in Global Health •PhD Applied Science: Global Public Health •MS Sustainable Development
OUR TRACK RECORD
RESEARCH
INNOVATION, QUALITY, SYNERGY
INNOVATION, QUALITY, SYNERGY
Research
Discovery and development of many products/clinical candidates: Cardiolite(myocardial imaging), Marluma (breast cancer detection), Tc99mplatelet GPIIb/IIIa antagonist for thrombus imaging in venous and arterial thrombotic disorders), anti-platelet/Anti-thrombotic agent, ultra-short acting beta blocker, Esmolol and analogs (cardiovascular safety), angiotensin receptor blocker, Losartan, and several key concepts in vascular, cardiovascular, oncology, and ophthalmology diseases. Dr Mousa’s Google Citation over 47,000 110-index 600, and h-index 100.
Significant and continuous contribution to the success of several regional, national, and international academic, biotechnology and pharmaceutical institutes. Dr. Mousa’s expertise in drug discovery and development during his 17 years at DuPont-Merck Pharmaceuticals help facilitate the success of several start up regional, national biotechnology and pharmaceutical companies. These include the followings: EmisphereTechnologies, AGTT Pharmaceuticals, Delcath Systems Inc., Cytogel, Inc., SelectXPharmaceuticals, Vascular Vision Pharmaceuticals Co., OtheraPharmaceuticals, PolyMedix, PharmionCorp, Nova Decision, DuPont, Merck, Sanofi-Aventis, GlaxoSmithKline, Pfizer, AstraZeneca, Leo Pharm, Takeda, Abbott, Hospira, Eisai pharmaceuticals, Endo Pharmaceuticals, and several other biotech and pharmaceutical companies. om the Middle East, Europe, Japan, China, South Korea, and others.
INNOVATION, QUALITY, SYNERGY
INNOVATION, QUALITY, SYNERGY
INNOVATION, QUALITY, SYNERGY
Sample Patents
Mousa SA, Rajabi M: Non-cleavable polymer conjugated with .alpha.V.beta.3 integrin thyroid antagonists. US Patent 10,201,616; Feb 12, 2019.
Mousa SA, Davis PJ: Methods for screening patients for resistance to angioinhibition, treatment and prophylaxis thereof. US Patent 10,060,934; Aug 28; 2018
Mousa SA, Davis PJ: Thyroid hormone analogs and methods of use. US Patent 9,980,933; May 29, 2018
Mousa SA, Davis PJ: Method and composition of thyroid hormone analogues and nanoformulationsthereof for treating inflammatory disorders. US Patent 10,130,686; Nov 20; 2018
Mousa SA, Davis PJ, Davis F: “Thyroid Hormone Analogs and Methods of Use”,
US Patent #US 7,785,632 B2, 2010.
Mousa SA, Davis PJ, Davis F: “Thyroid Hormone Analogs and Methods of Use”, Australian Patent #2004273986, 2010.
Mousa SA:Composition and method of use for combinations of anti-viral protease, polymerase inhibitors and natural bioactive compounds in the treatment of hepatitis C infection. US Patent 10,046,005; Aug 14; 2018
Mousa SA: Nano-targeted delivery of protease, polymerase inhibitors with or without immune modulators in the treatment of hepatitis C. US Patent 9,597,351; 2017.
Mousa SA: Composition and method for sulfated non-anticoagulant low molecular weight heparins in cancer and tumor metastasis. US Patent 9,572,831; 2017.
Mousa SA: Method and composition of glycosaminoglycans in sickle cell and vascular disorders. US Patent. 9,480,703; 2017.
Mousa SA: Method for treating occlusive vascular diseases & wound healing. US Patent 7,736,636.May2, 2000
Our Services
Program Development A to Z
Development and launching of underrepresented cutting-edgeundergraduate and graduate programs in biomedicine, health sciences and health professions, including curriculum, syllabi and resource needs.
- Cutting-edge and innovative workshops and conferences tailor-made to needs and empowerment of careers towards independence and self reliance.
- Paradigm shift in global public health from medicine to prevention per Center of Disease Control (CDC) and Council of Education in Public Health (CePH) taxanomy.
- Expert speakers and workshops in pre-clinical and clinical good laboratory practice (GLP) and good clinical research practices (GCP).
- Co-authoring of white papers and academic audits of pre-existing programs.
Research Training
- State-of-the-art and innovative training and co-supervision of post-doctorate fellows and graduate students in state-of-the-art methodologies with high impact journal deliverables.
- Collaborative research in pharmaceutical and natural product safety and efficacy.
- Building and enabling scientific network customized to our client base that address regional needs and challenges.
EMPOWERING THE NEXT GENERATION
Graduate and Post-doctoral Research training: MSc and PhD
- Pharmacology
- Oncology
- Hematology and Clinical Pathology
- Biomarker Discovery and Validation
- Biotechnology
- Nanomedicine
- Precision Medicine and Health
- Drug Development, Natural Products and Entrepreneurship
- Global Public Health
- Environmental Health and Toxicology
- Public Health Policy
SAMPLE PUBLICATIONS
Pharmaceuticals and Nanopharmaceuticals
Fujioka K, Fekry MI, Rumsey JM, Steiner T, Thompson D, Mousa SA. Preclinical assessment of drug-drug interaction of fb-PMT, a novel anti-cancer thyrointegrin αvβ3 antagonist. Clin Transl Sci. 2023 Jun;16(6):987-1001.
Hay BA, Godugu K, Darwish NHE, Fujioka K, Sudha T, Karakus OO, Mousa SA. New Thyrointegrin αvβ3 Antagonist with a Scalable Synthesis, Brain Penetration, and Potent Activity against Glioblastoma Multiforme. J Med Chem. 2021 May 13;64(9):6300-6309.
Godugu K, Hay BA, Glinsky GV, Mousa SA. Discovery of novel thyrointegrin αvβ3 antagonist fb-PMT (NP751) in the management of human glioblastoma multiforme. Neurooncol Adv. 2022 Dec 8;5(1): vdac180. doi: 10.1093/noajnl/vdac180. eCollection 2023 Jan-Dec.
Hercbergs A, Mousa SA, Lin HY, Davis PJ.What is thyroid function in your just-diagnosed cancer patient? Front Endocrinol (Lausanne). 2023 Feb 17;14:1109528.
Harakeh S, Almuhayawi MS, Akefe IO, Saber SH, Al Jaouni SK, Alzughaibi T, Almehmadi Y, Ali SS, Bharali DJ, Mousa S. Novel Pomegranate-Nanoparticles Ameliorate Cisplatin-Induced Nephrotoxicity and Improves Cisplatin Anti-Cancer Efficacy in Ehrlich Carcinoma Mice Model. Molecules. 2022 Feb 28;27(5):1605. doi: 10.3390/molecules27051605.
Ali MM, Ramadan MA, Ghazawy NA, Afify A, Mousa SA. Photochemical effect of silver nanoparticles on flesh fly larval biological system. Acta Histochem. 2022 Apr;124(3):151871. doi: 10.1016/j.acthis.2022.151871.
Darwish NHE, Glinsky GV, Sudha T, Mousa SA. Targeting Thyrointegrin αvβ3 Using Fluorobenzyl Polyethylene Glycol Conjugated Tetraiodothyroacetic Acid (NP751) in Acute Myeloid Leukemia. Front Oncol. 2022 Jan 27;11:793810. doi: 10.3389/fonc.2021.793810.
Phillips MC, Mousa SA. Clinical application of nano-targeting for enhancing chemotherapeutic efficacy and safety in cancer management. Nanomedicine (Lond). 2022 Mar;17(6):405-421.
Elnaggar MA, El-Fawal HAN, Allam NK. (2021). Biocompatible PCL-nanofibers scaffold with immobilized fibronectin and laminin for neuronal tissue regeneration. Mater Sci Eng C Mater Biol Appl. 2021 Feb;119:111550. doi: 10.1016/j.msec.2020.111550. Epub 2020 Sep 28.
Clinical Biomedicine and Neurodegeneration
Hegazi M, El-Jaafary S, Shebl S, El-Fawal H, Rizig M, Salama M (2024). Remote Sensing Data as a tool for studying environmental aspects of Parkinson’s diseases. J Parkinsons Dis 2024 Feb 23. doi: 10.3233/JPD-230382.
Shebl S, El-Jaafary S, El-Fawal H, Rizig M, Salama M (2024). Metabolomic Profiling Reveals Altered Phenylalanine Metabolism in Parkinson's Disease in An Egyptian Cohort. Frontiers in Molecular Biosciences, section Metabolomics. 11: doi: 10.3389/fmolb.2024.1341950
Mousa N, Abdellatif, A, Fahmy N, El-Fawal H, Osman A (2023). MicroRNAs as a tool for Differential Diagnosis of Neuromuscular Disorders. NeuromolecularMedicine doi: 10.1007/s12017-023-08763-0.
Youssef SH, Atalah HN, Badawy MT, El-Fawal HAN, Salama MM (2023). Three Neurodegenerative Diseases: A Single Hope. In: Mohamed, E. (eds) Handbook of Neurodegenerative Disorders. Springer, https://doi.org/10.1007/978-981-19-3949-5_3-1.
Moustafa, S.A., Deif, R., El-Fawal, H. (2022). Nutrigenomics and Neurodevelopmental Disorders. In: Salama, M. (eds) Nutrigenomics and the Brain. Nutritional Neurosciences. Springer, https://doi.org/10.1007/978-981-16-9205-5_6
El-Fawal, HAN. (2014). Neuroantibody (NAb) biomarkers: links and challenges in environmental neurodegeneration and autoimmunity. Autoimmune Disease 2014 2014:340875. doi: 10.1155/2014/340875.
El-Fawal, HAN, Waterman, SJ, De Feo, A. and Shamy, MY (1999). Neuroimmunotoxicology: Humoral assessment of neurotoxicity and autoimmune mechanisms. Environ. Hlth. Perspect. 107 (Supl5):767-775.
SAMPLE PUBLICATIONS
Health Policy
Abu El Kheir-Mataria W, Khadr Z, El-Fawal H, Chun S. (2024). COVID-19 vaccine intercountry distribution inequality and its underlying factors: a combined concentration index analysis and multiple linear regression analysis. Front. Public Health Sec. Life-Course Epidemiology and Social Inequalities in Health Volume 12 doi:0.3389/fpubh.2024.1348088
Abu El Kheir-Mataria W, El-Fawal H, Chun S. (2024). Global Health Governance: Changes of actors’ roles following Covid-19. Eastern Mediterranean Health Journal https://applications.emro.who.int/EMHJ/V30/02/1020-3397-2024-3002-93-102-eng.pdf
Abu El Kheir-Mataria W, El-Fawal H, Chun S. (2023). Global health governance performance during Covid-19, what needs to be changed? a delphisurvey study. Global Health. 31;19(1):24. doi: 10.1186/s12992-023-00921-0. PMID: 37004079; PMCID: PMC10063951.
Abu El Kheir-Mataria WA, Saleh BM, El-Fawal H and Chun S (2023) COVID-19 vaccine hesitancy among parents in Low- and Middle-Income Countries: A meta-analysis. Front. Public Health 11:1078009. doi: 10.3389/fpubh.2023.1078009
Educational Reference Works
El-Fawal , HAN., Rembisz, P., Alobaidi, R. and Mousa, SA. (2016). Chemotherapy mediated pain and peripheral neuropathy: Impact of oxidative stress and inflammation. In Oxidative damage and antioxidant imbalance: The science of biology in health and disease. First ed., D. Armstrong and R. D. Stratton. pp 367-388. John Wiley & Sons, Inc.
Yasin BR., El-Fawal HAN, Mousa SA. (2015). Date (Phoenix dactylifera) Polyphenolics and Other Bioactive Compounds: A Traditional Islamic Remedy's Potential in Prevention of Cell Damage, Cancer Therapeutics and Beyond. Int J Mol Sci. 17;16(12):30075-90. doi: 10.3390/ijms161226210.
El-Fawal, HAN. (2019). Neurotoxicology. In: Nriagu JO (ed.) Encyclopedia of Environmental Health, Second edition, volume 4, pp. 614-633: Elsevier.
El-Fawal, HAN (2016). The Tree and the Forest: A Need for Dialogue and a Collaborative Approach in the Safety of Nanomedicines. In Handbook of Clinical Nanomedicine Volume II: Law, Business, Regulation, Safety and Risk. R. Bawa, G. F. Audette and B. E. Reese. (Assistant Editors), pp: 1281-1289. Pan Stanford Publishing, Singapore.
Mousa SA, Bawa R, and Audette GF (Editors): The Road from Nanomedicine to Precision Medicine, Jenny Stanford Publishing (2020) – 1200+ pages, 36 chapters [ISBN 978-981-4800-59-4 (Hardcover), 978-0-429-29501-0 (eBook)].
Bowen N, Mousa SA. Role of antiplatelet therapy in neurosurgery: Efficacy and safety profiles. In: Loftus CM, ed. Anticoagulation and hemostasis in neurosurgery. Switzerland: Springer; 65-89, 2016.
Rajabi M, Srinivasan M, Mousa SA. Nanobiomaterials in drug delivery. In: Grumezescu, A, ed. Nanobiomaterials in drug delivery: William Andrew Publishing; 1-37:2016.
Srinivasan M, Rajabi M, A. Mousa SA. Nanobiomaterials in cancer therapy. In: Grumezescu, A, ed. Nanobiomaterials in cancer therapy: William Andrew Publishing; 57-89; 2016.
Mousa SA, Davis, PJ. Angiogenesis and anti-angiogenesis strategies in cancer. In: Mousa SA, Davis PJ, eds. Anti-angiogenesis Strategies in Cancer Therapies. Elsevier, London: Academic Press; 1-19:2016.